Interview, Fireside Chat, Lecture, Keynote
Juan Carlos Izpisua Belmonte, Altos Labs | All-In Summit 2024
All-In PodcastJuan Carlos Izpisua Belmonte, Chamath, Friedberg, Juan Carlos Espucía Belmonte, Juan Carlos Belmonde
- The discovery of a "fountain of youth" via Yamanaka factor-based cell reprogramming is anticipated to become a major global story, driven by technology described as resembling science fiction.
- Altos Labs has secured approximately three billion dollars in investment to conduct core research and parallel product development aimed at increasing human cellular buffer capacity.
- Experiments indicate that while specific mutations can reduce mouse lifespan to three or four months, the error rate for such accelerated aging models is less than 1%.
- The outlook identifies age as the primary risk factor for disease onset after 40–45 years, with the majority of diseases correlating to the passage of time rather than specific genetic mutations.
- Short pulses of Yamanaka factors are predicted to alter chromatin conformation, allowing mutated mice to live longer and healthier lives without correcting the underlying genetic error.
- The approach is expected to reverse or delay diseases across multiple organ systems, including kidney, skin, liver, and muscle, by enhancing cellular resilience.
- The strategy involves moving from isolated human cells to whole organisms, prioritizing safety and precautions during translation to human subjects.
- Specific applications include rejuvenating discarded organs ex vivo to improve transplant survival rates and targeting unhealthy cells to prevent aging signs like grey hair and wound healing delays.
- Future developments may utilize smaller molecules, peptides, or pills to achieve similar reprogramming effects, potentially making treatments safe and accessible.
- Lifestyle factors such as exercise show overlapping gene expression changes with reprogramming, while studies on metformin suggest potential benefits in primates for cognition and lifespan.
- Acute and deadly conditions, such as acute liver disease, are identified as initial targets for clinical translation.
- Partial cell reprogramming is predicted to be one of the most profoundly impactful technologies ever invented, with significant discoveries expected to translate to humans within the next decade.
- While animal models (mice, rats, monkeys) show strong parallels to humans, the speaker notes that full replication in humans will require time and further validation.